$3.37
−1.17%Nov 3, 2026, 12:00 UTC
ProMIS Neurosciences announced that it will report third-quarter 2026 financial results and provide a business update on November 12, 2026, followed by a conference call and webcast at 4:30 p.m.
Source:Aug 14, 2026, 02:04 UTC
Promis Neurosciences reported its second-quarter 2026 financial results.
Source:Jul 28, 2026, 10:00 UTC
ProMIS Neurosciences reported positive blinded six-month interim safety and biomarker data for its drug candidate PMN310 in the PRECISE-AD Phase 1b Alzheimer's disease trial.
Jul 14, 2026, 06:30 UTC
ProMIS Neurosciences reported first human evidence of amyloid-beta oligomer target engagement by PMN310 at AAIC 2026.